Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration.

Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ.

J Urol. 2013 May;189(5):1702-6. doi: 10.1016/j.juro.2012.11.149. Epub 2012 Nov 30.

2.
3.

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.

Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW.

J Urol. 2003 Sep;170(3):723-6.

PMID:
12913682
4.
5.
6.

Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy.

Lazzeri M, Briganti A, Scattoni V, Lughezzani G, Larcher A, Gadda GM, Lista G, Cestari A, Buffi N, Bini V, Freschi M, Rigatti P, Montorsi F, Guazzoni G.

J Urol. 2012 Oct;188(4):1137-43. doi: 10.1016/j.juro.2012.06.017. Epub 2012 Aug 15.

PMID:
22901578
7.

Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection.

Jansen FH, Roobol M, Bangma CH, van Schaik RH.

Clin Chem. 2008 Dec;54(12):1999-2006. doi: 10.1373/clinchem.2007.102699. Epub 2008 Oct 16.

8.

Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays.

Fillée C, Tombal B, Philippe M.

Clin Chem Lab Med. 2010 Feb;48(2):285-8. doi: 10.1515/CCLM.2010.039.

PMID:
20001849
9.

The prostate health index selectively identifies clinically significant prostate cancer.

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

J Urol. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. Epub 2014 Nov 15.

10.

Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, Friedersdorff F.

Clin Chem. 2013 Jan;59(1):280-8. doi: 10.1373/clinchem.2012.195560. Epub 2012 Dec 4.

11.

Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.

Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ, Brawer MK, Schwartz MK, Vessella RL, Loughlin KR, Johnston DA, Babaian RJ.

J Urol. 2002 May;167(5):2017-23; discussion 2023-4.

PMID:
11956430
12.

[Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients].

Houlgatte A, Vincendeau S, Desfemmes F, Ramirez J, Benoist N, Bensalah K, Durand X.

Prog Urol. 2012 May;22(5):279-83. doi: 10.1016/j.purol.2011.09.009. Epub 2011 Oct 24. French.

PMID:
22515924
13.

Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy.

Lughezzani G, Lazzeri M, Larcher A, Lista G, Scattoni V, Cestari A, Buffi NM, Bini V, Guazzoni G.

J Urol. 2012 Oct;188(4):1144-50. doi: 10.1016/j.juro.2012.06.025. Epub 2012 Aug 15.

PMID:
22901589
14.

Can percent free prostate-specific antigen reduce the need for prostate biopsy?

Lieberman S.

Eff Clin Pract. 1999 Nov-Dec;2(6):266-71.

PMID:
10788024
15.

Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.

Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A.

Clin Chem. 2013 Jan;59(1):306-14. doi: 10.1373/clinchem.2012.195784. Epub 2012 Dec 4.

16.

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

J Urol. 2012 Oct;188(4):1131-6. doi: 10.1016/j.juro.2012.06.009. Epub 2012 Aug 15.

17.

20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.

Stephan C, Bangma C, Vignati G, Bartsch G, Lein M, Jung K, Philippe M, Semjonow A, Catalona WJ.

Int J Biol Markers. 2009 Apr-Jun;24(2):65-9.

PMID:
19634108
18.

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.

Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G.

BJU Int. 2013 Aug;112(3):313-21. doi: 10.1111/bju.12217.

19.

Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.

Na R, Ye D, Liu F, Chen H, Qi J, Wu Y, Zhang G, Wang M, Wang W, Sun J, Yu G, Zhu Y, Ren S, Zheng SL, Jiang H, Sun Y, Ding Q, Xu J.

Prostate. 2014 Nov;74(15):1569-75. doi: 10.1002/pros.22876. Epub 2014 Aug 31.

PMID:
25176131
20.

Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.

Letran JL, Blase AB, Loberiza FR, Meyer GE, Ransom SD, Brawer MK.

J Urol. 1998 Aug;160(2):426-9.

PMID:
9679891

Supplemental Content

Support Center